Fortrea To Manage Incannex's FDA IND Opening Phase 2/3 Trial Of Its Dronabinol-Based Drug For Obstructive Sleep Apnea
Portfolio Pulse from Vuk Zdinjak
Incannex Healthcare Limited (NASDAQ:IXHL) has engaged Fortrea (NASDAQ:FTRE) to manage the IND opening phase 2/3 clinical trial of its drug IHL-42X for the treatment of obstructive sleep apnea. The trial will assess the safety and efficacy of IHL-42X over a 52-week treatment period. The initial phase 2 trial demonstrated a significant reduction in the Apopnea Hypopnea Index score and improved sleep quality.
July 18, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fortrea has been engaged by Incannex to manage the phase 2/3 trial of IHL-42X.
Fortrea's engagement in the management of the phase 2/3 trial for IHL-42X could potentially increase its visibility and reputation in the healthcare sector, which could have a positive impact on its stock in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Incannex is initiating a phase 2/3 trial for its sleep apnea drug IHL-42X, which showed promising results in the initial phase 2 trial.
The news of the phase 2/3 trial for IHL-42X is directly related to Incannex and its future prospects. The promising results from the initial trial could potentially boost investor confidence and have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100